ReCode Therapeutics

Menlo Park, CA · Founded 2015 · Biotech · Private

Optimized mRNA and gene correction medicines with targeted organ/tissue delivery platform

Claim this profile

Follows are private to you and power your alerts

Updated · recodetx.com

Sector
Biotech
Headquarters
Menlo Park, CA
Founded
2015
Latest Form D
$29.4M, Oct 2025
Total capital
$97.4M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$97.4M
4 Form D · last Oct 2025
12 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
7
33 pending · first 2024
Rank in peer group#213 of 1449

Capital timeline

20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $97.4M1st Form D$500K2nd Form D$27.5M3rd Form D$40M4th Form D$29.4M
20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $97.4M2nd Form D$27.5M3rd Form D$40M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$29.4M
  • Private capital raisedForm D · SEC · 3rd filing$40M
  • Private capital raisedForm D · SEC · 2nd filing$27.5M
  • Private capital raisedForm D · SEC · 1st filing$500K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#213 · top 15%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Alan S. ColowickDirectorNamed in SEC Form D filings
  • Arthur E JohnsonExecutive Officer, DirectorNamed in SEC Form D filings
  • Basheer S. ZadaDirectorNamed in SEC Form D filings
  • David S. LockhartExecutive OfficerNamed in SEC Form D filings
  • Dean S. MitchellDirectorNamed in SEC Form D filings
  • Edward J HurwitzDirectorNamed in SEC Form D filings
Show all 19 people
  • Helen S. KimDirectorNamed in SEC Form D filings
  • Inai S. ParkDirectorNamed in SEC Form D filings
  • Julia S. EastlandExecutive OfficerNamed in SEC Form D filings
  • Kouki S. HarasakiDirectorNamed in SEC Form D filings
  • Michael J TorresDirectorNamed in SEC Form D filings
  • Oleg S. NodelmanDirectorNamed in SEC Form D filings
  • Patricia S. MillicanDirectorNamed in SEC Form D filings
  • Peter A. ThompsonDirectorNamed in SEC Form D filings
  • Rakhshita S. DharDirectorNamed in SEC Form D filings
  • Rana S. Al-HallaqDirectorNamed in SEC Form D filings
  • RA S. Session IIDirectorNamed in SEC Form D filings
  • Shehnaaz SulimanExecutive Officer, DirectorNamed in SEC Form D filings
  • Trisha S. MillicanDirectorNamed in SEC Form D filings

What it has protected

USPTO · 7 granted of 40
Show all 40 patent records
  • Lipid Nanoparticle Compositions And Uses ThereofJul 16, 2026 · Application 19400701Pending
  • Lipid Nanoparticle Compositions And Uses ThereofMar 24, 2026 · US 12,582,611Granted
  • Method For Quantifying An Amount Of Capped Messenger RnaFeb 17, 2026 · US 12,553,042Granted
  • Lipid Nanoparticle Compositions And Uses ThereofSep 18, 2025 · Application 19182477Pending
  • Compositions, Methods And Uses For Treating Cystic Fibrosis And Related DisordersSep 11, 2025 · Application 18553975Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofSep 4, 2025 · Application 19006037Pending
  • Lipid Nanoparticle Compositions And Uses ThereofJul 22, 2025 · US 12,364,773Granted
  • Lipid Nanoparticle Compositions And Uses ThereofJun 24, 2025 · US 12,337,068Granted
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofApr 10, 2025 · Application 18283143Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofMar 25, 2025 · US 12,257,318Granted
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofJan 16, 2025 · Application 18283523Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofDec 5, 2024 · Application 18282699Pending
  • Compositions And Methods For Targeted Delivery To CellsNov 28, 2024 · Application 18797360Pending
  • Compositions And Methods For Targeted Delivery To CellsNov 28, 2024 · Application 18780382Pending
  • Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778717Pending
  • Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778746Pending
  • Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778439Pending
  • Compositions And Methods For Targeted Delivery To CellsNov 14, 2024 · Application 18778429Pending
  • Lipid Nanoparticle Compositions And Uses ThereofNov 5, 2024 · US 12,133,923Granted
  • Compositions And Methods For Targeted Delivery To CellsOct 22, 2024 · US 12,121,610Granted
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofSep 19, 2024 · Application 18532995Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofSep 12, 2024 · Application 18596141Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofAug 22, 2024 · Application 18596151Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofAug 8, 2024 · Application 18596148Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofJul 25, 2024 · Application 18420141Pending
  • Polynucleotide Compositions, Related Formulations, And Methods Of Use ThereofApr 18, 2024 · Application 18282181Pending
  • Compositions And Methods For Targeted Delivery To CellsOct 26, 2023 · Application 18312305Pending
  • Compositions And Methods For Targeted Delivery To CellsSep 21, 2023 · Application 18311274Pending
  • Lipid Nanoparticle Compositions And Uses ThereofApplication 63725936Pending
  • Lipid Nanoparticle Compositions And Uses ThereofApplication PCTUS2024057850Pending
  • Systems And Methods For Generating Lipid NanoparticlesApplication PCTUS2025016069Pending
  • Lipid Nanoparticles For Hepatic DeliveryApplication 63647251Pending
  • Lipid Nanoparticle Compositions And Uses Thereof And Method For Quantifying An Amount Of Capped Messenger RnaApplication PCTUS2024057849Pending
  • Lipid Nanoparticles For Extrahepatic DeliveryApplication 63647166Pending
  • Lipid Nanoparticles For Extrahepatic DeliveryApplication 63659796Pending
  • Lipid Nanoparticle Compositions And Uses ThereofApplication PCTUS2024057852Pending
  • Lipid Nanoparticles For Extrahepatic DeliveryApplication PCTUS2025028959Pending
  • Lipid Nanoparticles For Hepatic DeliveryApplication 63737003Pending
  • Lipid Nanoparticle Compositions And Uses ThereofApplication 63605392Pending
  • Systems And Methods For Generating Lipid NanoparticlesApplication 63737069Pending
  • RallybioSimilar federal contract value in Biotech · null in contracts
  • Autobahn TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Amicus TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • NuPeak Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • D3 BioSimilar federal contract value in Biotech · null in contracts
  • HOLOCLARA, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .